SUCLA2
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial
Also known as: LINC00444, SUCB1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9P2R7
- Gene
- SUCLA2
- Ensembl
- ENSG00000136143
- Chromosome
- 13
- Canonical length
- 463 aa
- Protein class
- Citric acid cycle related proteins, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Mitochondria
OverviewNCBI Gene
Succinyl-CoA synthetase (SCS) is a mitochondrial matrix enzyme that acts as a heterodimer, being composed of an invariant alpha subunit and a substrate-specific beta subunit. The protein encoded by this gene is an ATP-specific SCS beta subunit that dimerizes with the SCS alpha subunit to form SCS-A, an essential component of the tricarboxylic acid cycle. SCS-A hydrolyzes ATP to convert succinate to succinyl-CoA. Defects in this gene are a cause of myopathic mitochondrial DNA depletion syndrome. A pseudogene of this gene has been found on chromosome 6. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
463 residues, UniProt reviewed canonical sequence.
>Q9P2R7|SUCLA2
1 MAASMFYGRL VAVATLRNHR PRTAQRAAAQ VLGSSGLFNN HGLQVQQQQQ RNLSLHEYMS
61 MELLQEAGVS VPKGYVAKSP DEAYAIAKKL GSKDVVIKAQ VLAGGRGKGT FESGLKGGVK
121 IVFSPEEAKA VSSQMIGKKL FTKQTGEKGR ICNQVLVCER KYPRREYYFA ITMERSFQGP
181 VLIGSSHGGV NIEDVAAESP EAIIKEPIDI EEGIKKEQAL QLAQKMGFPP NIVESAAENM
241 VKLYSLFLKY DATMIEINPM VEDSDGAVLC MDAKINFDSN SAYRQKKIFD LQDWTQEDER
301 DKDAAKANLN YIGLDGNIGC LVNGAGLAMA TMDIIKLHGG TPANFLDVGG GATVHQVTEA
361 FKLITSDKKV LAILVNIFGG IMRCDVIAQG IVMAVKDLEI KIPVVVRLQG TRVDDAKALI
421 ADSGLKILAC DDLDEAARMV VKLSEIVTLA KQAHVDVKFQ LPILocalizationUniProt · AlphaFold · HPA
Whether an antibody against SUCLA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 254 nTPM
Expression across tissuesHPA
Tissue
- tongue: 254 nTPM
- skeletal muscle: 217 nTPM
- heart muscle: 94 nTPM
- kidney: 72 nTPM
- parathyroid gland: 67 nTPM
- duodenum: 55 nTPM
Single-cell type
- late spermatids: 486 nCPM
- early spermatids: 424 nCPM
- endometrial luminal cells: 180 nCPM
- adipocytes: 165 nCPM
- myonuclei: 159 nCPM
- late primary spermatocytes: 156 nCPM
Immune cell
- myeloid DC: 63 nTPM
- intermediate monocyte: 54 nTPM
- NK-cell: 52 nTPM
- classical monocyte: 50 nTPM
- plasmacytoid DC: 50 nTPM
- naive CD4 T-cell: 48 nTPM
Brain region
- hypothalamus: 72 nTPM
- cerebellum: 69 nTPM
- cerebral cortex: 69 nTPM
- white matter: 64 nTPM
- choroid plexus: 63 nTPM
- thalamus: 63 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SUCLA2.
Disease | AllUniProt
Conditions SUCLA2 is implicated in, by any mechanism.
- Mitochondrial DNA depletion syndrome 5 (MTDPS5) MIM:612073
Disease | GeneticClinVar
34 pathogenic / likely-pathogenic of 493 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
- Inborn genetic diseases
- SUCLA2-related disorder
- Familial prostate cancer
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.63
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.02
- DepMap mean gene effect
- -0.18
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- succinate metabolic process
- succinyl-CoA catabolic process
- succinyl-CoA metabolic process
- tricarboxylic acid cycle
- succinyl-CoA pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Succinate--CoA ligase-like, beta subunit
- ATP-citrate synthase/succinyl-CoA ligase, C-terminal domain
- ATP-grasp fold
- ATP-grasp fold, succinyl-CoA synthetase-type
- ATP-grasp fold, subdomain 1
- Succinyl-CoA synthetase-like
- Succinyl-CoA synthetase, beta subunit, conserved site
- CoA-ligase
- ATP-grasp domain
- Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SUCLA2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SUCLA2 as an antibody target. Whether an autoantibody or antibody against SUCLA2 could matter depends on whether native SUCLA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SUCLA2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SUCLA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...